Payment overview · 2025
General Payments
$2,534.21
146 reported records · 44 companies
Healthcare provider profile · identity verified
James M Patton, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · ASHEVILLE, NC · NPI 1518945690
Verified facts
What the public records show
CMS Open Payments records show James M Patton, MD received $2,534.21 in general payments during 2025 across 146 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 13.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 55 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Nuplazid, Nurtec Odt, Tysabri, Ubrelvy, Xeomin.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Rytary by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TYSABRI as an associated drug or biological on 12612 records involving 3572 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Tysabri by this doctor in 2024.
Merz Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xeomin as an associated drug or biological on 8663 records involving 4073 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Xeomin by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $340.39 | 13.4% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $313.68 | 12.4% | 56 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $162.28 | 6.4% | 9 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $101.18 | 4.0% | 4 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$85.49 | 3.4% | 2 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $70.36 | 2.8% | 3 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $67.49 | 2.7% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $65.01 | 2.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $64.27 | 2.5% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $64.02 | 2.5% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $61.86 | 2.4% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $58.86 | 2.3% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $56.34 | 2.2% | 2 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $55.78 | 2.2% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $53.06 | 2.1% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $51.85 | 2.0% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $51.43 | 2.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $50.79 | 2.0% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $50.38 | 2.0% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $49.69 | 2.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.50 | 1.9% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $46.03 | 1.8% | 2 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $45.62 | 1.8% | 2 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $44.74 | 1.8% | 2 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $40.81 | 1.6% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.24 | 1.6% | 1 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $33.05 | 1.3% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $30.95 | 1.2% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $27.78 | 1.1% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $26.23 | 1.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $25.68 | 1.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.57 | 1.0% | 1 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $23.07 | 0.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.18 | 0.9% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$21.82 | 0.9% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $21.18 | 0.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.61 | 0.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.18 | 0.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.60 | 0.7% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $17.90 | 0.7% | 1 | 2025 |
| CONMED Corporation | Unresolved — no canonical attribution shown | $16.37 | 0.7% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $16.13 | 0.6% | 1 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $15.50 | 0.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.26 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,347.86 | 143 |
| Education | $186.35 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $308.50 | 55 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $277.58 | 51 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $180.40 | 9 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $101.18 | 4 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $94.13 | 6 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $85.49 | 2 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $69.03 | 4 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $65.01 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $64.27 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $64.27 | 3 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $61.86 | 3 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $58.86 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $56.34 | 2 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $55.78 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $51.85 | 2 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $51.43 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $50.79 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $50.38 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $49.69 | 2 | 2025 |
Source payment records
|
|||||
| Apokyn Normalized: apokyn |
Drug | MDD US Operations, LLC | $47.09 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $46.03 | 2 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $45.62 | 2 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $43.78 | 2 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $43.30 | 2 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $42.28 | 2 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $40.81 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $40.24 | 1 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $33.05 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $30.95 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $28.86 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $27.98 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $27.78 | 1 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $26.23 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $25.68 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $25.08 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $24.57 | 1 | 2025 |
Source payment records
|
|||||
| QALSODY Normalized: qalsody |
Drug | Biogen, Inc. | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| Ormalvi Normalized: ormalvi |
Drug | Cycle Pharmaceuticals Inc | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| Xadago Normalized: xadago |
Drug | MDD US Operations, LLC | $23.27 | 1 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| BREKIYA Normalized: brekiya |
Drug | Amneal Pharmaceuticals LLC | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| VISICLEAR Normalized: visiclear |
Device | CONMED Corporation | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $16.33 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 175 | exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TYSABRI tysabri |
2025 | Tysabri | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 45 | exact normalized | Medicare Part D |
| Xeomin xeomin |
2025 | Xeomin | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
175 | 61 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
65 | 17 |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TYSABRI open payments reported associated product |
CMS Open Payments — General Payments 12612 supporting records · 3572 recipient NPIs · example record 1208299693 |
Tysabri · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Merz Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | Xeomin open payments reported associated product |
CMS Open Payments — General Payments 8663 supporting records · 4073 recipient NPIs · example record 1232555385 |
Xeomin · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa | Carbidopa/Levodopa | 922 | 275 |
| Gabapentin | Gabapentin | 483 | 136 |
| Baclofen | Baclofen | 299 | 74 |
| Tizanidine Hcl | Tizanidine Hcl | 258 | 71 |
| Donepezil Hcl | Donepezil Hcl | 254 | 70 |
| Clonazepam | Clonazepam | 249 | 53 |
| Primidone | Primidone | 245 | 77 |
| Propranolol Hcl | Propranolol Hcl | 199 | 66 |
| Botox | Onabotulinumtoxina | 175 | 61 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 153 | 48 |
| Topiramate | Topiramate | 135 | 45 |
| Trazodone Hcl | Trazodone Hcl | 124 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 119 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 113 | 26 |
| Diazepam | Diazepam | 106 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 30 |
| Memantine Hcl | Memantine Hcl | 102 | 26 |
| Propranolol Hcl Er | Propranolol Hcl | 97 | 23 |
| Pregabalin | Pregabalin | 88 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 23 |
| Tramadol Hcl | Tramadol Hcl | 77 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 73 | 28 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 72 | 19 |
| Meloxicam | Meloxicam | 68 | 17 |
| Lamotrigine | Lamotrigine | 67 | 16 |
| Lorazepam | Lorazepam | 66 | 14 |
| Rytary | Carbidopa/Levodopa | 65 | 17 |
| Bupropion Xl | Bupropion Hcl | 63 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 15 |
| Prednisone | Prednisone | 59 | 34 |
| Mirtazapine | Mirtazapine | 55 | 19 |
| Rasagiline Mesylate | Rasagiline Mesylate | 54 | 15 |
| Alprazolam | Alprazolam | 52 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 49 | 11 |
| Nuplazid | Pimavanserin Tartrate | 46 | suppressed |
| Ubrelvy | Ubrogepant | 45 | 11 |
| Amantadine | Amantadine Hcl | 43 | 19 |
| Modafinil | Modafinil | 43 | 12 |
| Xeomin | Incobotulinumtoxina | 43 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 41 | 11 |
| Midodrine Hcl | Midodrine Hcl | 41 | suppressed |
| Lacosamide | Lacosamide | 39 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 38 | 11 |
| Entacapone | Entacapone | 37 | suppressed |
| Levetiracetam | Levetiracetam | 37 | 12 |
| Nurtec Odt | Rimegepant Sulfate | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 15 |
| Ropinirole Er | Ropinirole Hcl | 34 | suppressed |
| Temazepam | Temazepam | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 33 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 30 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 27 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Lamotrigine Er | Lamotrigine | 24 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 24 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Gablofen | Baclofen | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 18 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 17 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 15 | suppressed |
| Lyrica | Pregabalin | 15 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 15 | suppressed |
| Tysabri | Natalizumab | 15 | suppressed |
| Droxidopa | Droxidopa | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Topiramate Er | Topiramate | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Tetrabenazine | Tetrabenazine | 12 | suppressed |
| Clobazam | Clobazam | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,534.21 · 146 records | Teva Pharmaceuticals USA, Inc. | ACTHAR, AUSTEDO XR, Apokyn, BOTOX, BREKIYA, BRIUMVI, Bafiertam, CREXONT, DAXXIFY, Dysport, EPIDIOLEX, Exablate, FIRDAPSE, FYCOMPA, Fintepla, HYQVIA, INBRIJA, INFINITY, INGREZZA, KESIMPTA, KEVEYIS, KISUNLA, LUMRYZ, Leqembi, NUPLAZID, NURTEC ODT, Nayzilam, Ocrevus Zunovo, Ormalvi, PERCEPT PC BRAINSENSE, PONVORY, PRECIVITYAD2, QALSODY, QULIPTA, QUTENZA, REXULTI, Radicava, SKYCLARYS, SPINRAZA, Symbravo, TRUDHESA, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VISICLEAR, VUMERITY, VYVGART HYTRULO, WAINUA, Xadago, Xeomin, ZAVZPRET, ZEPOSIA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error